Next Article in Journal
Mosquito Mycobiota: An Overview of Non-Entomopathogenic Fungal Interactions
Next Article in Special Issue
Comparative Pathology of Pseudorabies in Different Naturally and Experimentally Infected Species—A Review
Previous Article in Journal
Molecular Characterization of Echinococcus granulosus sensu lato from Humans in Slovenia
Previous Article in Special Issue
Monitoring of Pseudorabies in Wild Boar of Germany—A Spatiotemporal Analysis
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Review

Aujeszky’s Disease and the Development of the Marker/DIVA Vaccination Concept

Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Südufer 10, 17493 Greifswald-Insel Riems, Germany
Pathogens 2020, 9(7), 563; https://doi.org/10.3390/pathogens9070563
Received: 23 June 2020 / Revised: 2 July 2020 / Accepted: 6 July 2020 / Published: 12 July 2020
(This article belongs to the Special Issue Pseudorabies Virus Infections)
Aujeszky’s disease or pseudorabies is an infection of animals caused by Suid alphaherpesvirus 1, also designated as pseudorabies virus (PrV). Whereas many mammals are susceptible to PrV, only pigs are able to survive productive infection. Early reports on this disease originate from cattle and companion animals with the hallmark sign of “mad itch”, meaning development of pruritus. Although first reports date back to the early 19th century, it was Aladár Aujeszky who in 1902 described this disease, which has since been named after him, as a separate entity. AD expanded in the 20th century, despite efforts to control this infection in the growing pig farming industry. Live-attenuated vaccines were developed in the early 1960s, which assisted early eradication efforts. A major breakthrough in animal vaccinology occurred in the mid-1980s, when it was found that several live-attenuated PrV vaccine strains lacked a significant portion of the genome, including the gene encoding a major immunogenic viral envelope glycoprotein. Upon the development of a suitable serological assay, the first marker vaccine/DIVA concept (differentiating infected from vaccinated animals) was developed. Moreover, the first genetically modified live vaccines emanated from molecular work on PrV. Thus, AD serves as a hallmark for the history of veterinary virology as well as for pioneering novel strategies for controlling animal infectious diseases. View Full-Text
Keywords: pseudorabies; Aujeszky’s disease; Aladár Aujeszky; pseudorabies virus; marker vaccine; DIVA strategy pseudorabies; Aujeszky’s disease; Aladár Aujeszky; pseudorabies virus; marker vaccine; DIVA strategy
Show Figures

Figure 1

MDPI and ACS Style

Mettenleiter, T.C. Aujeszky’s Disease and the Development of the Marker/DIVA Vaccination Concept. Pathogens 2020, 9, 563. https://doi.org/10.3390/pathogens9070563

AMA Style

Mettenleiter TC. Aujeszky’s Disease and the Development of the Marker/DIVA Vaccination Concept. Pathogens. 2020; 9(7):563. https://doi.org/10.3390/pathogens9070563

Chicago/Turabian Style

Mettenleiter, Thomas C. 2020. "Aujeszky’s Disease and the Development of the Marker/DIVA Vaccination Concept" Pathogens 9, no. 7: 563. https://doi.org/10.3390/pathogens9070563

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop